Madrigal Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Madrigal Pharmaceuticals generated cash of -$324,230,000, which is less than the previous year. Cash used in financing activities reached the amount of $595,116,000 last year. Net change in cash is therefore -$231,634,000.
Cash Flow
| 2014 | -78.92M | -8.83M | 85.29M |
|---|---|---|---|
| 2015 | -71.44M | 20M | 40.38M |
| 2016 | -17.60M | 21.99M | 14.45M |
| 2017 | -22.31M | -22.00M | 173.80M |
| 2018 | -25.50M | -380.07M | 314.33M |
| 2019 | -41.62M | 30.70M | 235K |
| 2020 | -157.56M | 159.78M | 5.08M |
| 2021 | -183.91M | -5.05M | 171.23M |
| 2022 | -224.85M | 206.68M | 313.45M |
| 2023 | -324.23M | -502.52M | 595.11M |
MDGL Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 331.54M | 36.26M | 54.00M | 46.69M | 57.37M | 148.62M | 19.14M | 306.24K | 46.02M | 48.49M |
Operating activities | ||||||||||
Net income | -373.63M | -295.35M | -241.84M | -202.24M | -83.94M | -32.81M | -31.15M | -26.38M | -68.67M | -86.16M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 527K | 467K | 405K | 471K | 112K | 96K | 77K | 156 | 662K | 673K |
Stock-based compensation expense | 49.73M | 31.62M | 26.87M | 20.73M | 22.75M | 0 | 3.25M | 8.67M | 4.3M | 7.43M |
| Deferred income tax benefit | 49.73M | 31.62M | 26.87M | 20.73M | 22.75M | 0 | 3.25M | 8.67M | 4.3M | 7.43M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.33M | 38.82K | -40 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -44.71M | 0 | 0 |
Accounts payable | 4.21M | 2.45M | 20.36M | -161K | -1.30M | 558K | 917K | -128.05K | -1.84M | -3.45M |
Cash generated by operating activities | -324.23M | -224.85M | -183.91M | -157.56M | -41.62M | -25.50M | -22.31M | -17.60M | -71.44M | -78.92M |
Investing activities | ||||||||||
Purchases Of Investments | -834.43M | -143.47M | -394.12M | -329.34M | -619.30M | -614.35M | -70.21M | -10.69M | -117.13M | -93.84M |
Investments In Property Plant And Equipment | -1.47M | -217K | -209K | -334K | -172K | -22K | -125K | -3.08K | -58K | -144K |
Acquisitions Net | 0 | -3K | 787K | 1.92M | 3.64M | -3.67M | 0 | 5.84M | 0 | 8.8K |
Cash generated by investing activities | -502.52M | 206.68M | -5.05M | 159.78M | 30.70M | -380.07M | -22.00M | 21.99M | 20M | -8.83M |
Financing activities | ||||||||||
Common Stock Issued | 260.18M | 255.38M | 170.20M | 4.42M | 235K | 311.82M | 173.80M | 5.95M | 6 | 94.78M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 65M | 50M | 0 | 0 | 0 | 0 | 0 | -8.50M | 3.3M | -9.49M |
Cash used in financing activities | 595.11M | 313.45M | 171.23M | 5.08M | 235K | 314.33M | 173.80M | 14.45M | 40.38M | 85.29M |
Net Change In Cash | -231.63M | 295.28M | -17.73M | 7.30M | -10.68M | -91.24M | 129.48M | 18.83M | -11.05M | -2.46M |
Cash at end of period | 99.91M | 331.54M | 36.26M | 54.00M | 46.69M | 57.37M | 148.62M | 19.14M | 34.96M | 46.02M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |